TAVI期间继续与中断口服抗凝治疗的比较
本研究为国际、开放标签、随机、非劣效性试验,纳入正在接受口服抗凝治疗并计划行TAVI的患者,1:1随机分配至围术期继续或中断口服抗凝治疗。改良意向治疗人群共858例(继续组431例,中断组427例)。主要终点(心血管原因死亡、任何原因卒中、心肌梗死、主要血管并发症或大出血的复合终点,TAVI后30天内)在继续组发生71例(16.5%),中断组63例(14.8%),风险差1.7个百分点(95%CI -3.1至6.6),非劣效性P=0.18。结论:围术期继续口服抗凝治疗未能达到不劣于中断口服抗凝治疗的非劣效性标准。
要点
- TAVI围术期继续口服抗凝治疗的主要终点事件发生率16.5%(71/431),中断组14.8%(63/427),风险差1.7个百分点(95%CI -3.1至6.6),非劣效性P=0.18,未达非劣效。
- 血栓栓塞事件:继续组8.8%(38/431) vs 中断组8.2%(35/427),风险差0.6个百分点(95%CI -3.1至4.4)。
- 出血事件:继续组31.1%(134/431) vs 中断组21.3%(91/427),风险差9.8个百分点(95%CI 3.9至15.6)。
- 对于计划行TAVI且合并口服抗凝治疗指征的患者,围术期继续口服抗凝治疗未能证明不劣于中断策略。
适用人群与场景
- 正在接受口服抗凝治疗并计划行经导管主动脉瓣植入术(TAVI)的患者。
处置流程与药物剂量
- 围术期继续口服抗凝治疗(继续组)或围术期中断口服抗凝治疗(中断组),具体中断方案原文未描述。
研究设计与关键结果
- 研究类型:国际、开放标签、随机、非劣效性试验;改良意向治疗人群858例,继续组431例,中断组427例。
- 主要终点(心血管原因死亡、任何原因卒中、心肌梗死、主要血管并发症或大出血的复合终点,TAVI后30天内):继续组71例(16.5%) vs 中断组63例(14.8%),风险差1.7个百分点(95%CI -3.1至6.6),非劣效性P=0.18。
- 血栓栓塞事件:继续组38例(8.8%) vs 中断组35例(8.2%),风险差0.6个百分点(95%CI -3.1至4.4)。
- 出血事件:继续组134例(31.1%) vs 中断组91例(21.3%),风险差9.8个百分点(95%CI 3.9至15.6)。
证据类型、等级与局限
- 证据类型:国际、开放标签、随机、非劣效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于计划行TAVI且合并口服抗凝治疗指征的患者,围术期继续口服抗凝治疗未能达到不劣于中断口服抗凝治疗的非劣效性标准,作者结论未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: One third of patients undergoing transcatheter aortic-valve implantation (TAVI) have an indication for oral anticoagulation owing to concomitant diseases. Interruption of oral anticoagulation during TAVI may decrease the risk of bleeding, whereas continuation may decrease the risk of thromboembolism.
METHODS: We conducted an international, open-label, randomized, noninferiority trial involving patients who were receiving oral anticoagulants and were planning to undergo TAVI. Patients were randomly assigned in a 1:1 ratio to periprocedural continuation or interruption of oral anticoagulation. The primary outcome was a composite of death from cardiovascular causes, stroke from any cause, myocardial infarction, major vascular complications, or major bleeding within 30 days after TAVI.
RESULTS: A total of 858 patients were included in the modified intention-to-treat population: 431 were assigned to continuation and 427 to interruption of oral anticoagulation. A primary-outcome event occurred in 71 patients (16.5%) in the continuation group and in 63 (14.8%) in the interruption group (risk difference, 1.7 percentage points; 95% confidence interval [CI], -3.1 to 6.6; P = 0.18 for noninferiority). Thromboembolic events occurred in 38 patients (8.8%) in the continuation group and in 35 (8.2%) in the interruption group (risk difference, 0.6 percentage points; 95% CI, -3.1 to 4.4). Bleeding occurred in 134 patients (31.1%) in the continuation group and in 91 (21.3%) in the interruption group (risk difference, 9.8 percentage points; 95% CI, 3.9 to 15.6).
CONCLUSIONS: In patients undergoing TAVI with a concomitant indication for oral anticoagulation, periprocedural continuation was not noninferior to interruption of oral anticoagulation during TAVI with respect to the incidence of a composite of death from cardiovascular causes, stroke, myocardial infarction, major vascular complications, or major bleeding at 30 days. (Funded by the Netherlands Organization for Health Research and Development and the St. Antonius Research Fund; POPular PAUSE TAVI ClinicalTrials.gov number, NCT04437303.).
参考来源
- van Ginkel DJ, Bor WL, Aarts HM, et al. Continuation versus Interruption of Oral Anticoagulation during TAVI. N Engl J Med. 2024. PMID: 39216096. doi:10.1056/NEJMoa2407794
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。